Klinicheskoe znachenie peroral'nykh lekarstvennykh form al'fag adrenoblokatorov modifitsirovannogo vysvobozhdeniya v lechenii patsientov s dobrokachestvennoy gipertrofiey predstatel'noy zhelezy
- Authors: Leonova M.V.1
-
Affiliations:
- Issue: No 20 (2009)
- Pages: 36-43
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278161
- ID: 278161
Cite item
Full Text
Abstract
Представлен обзор особенностей фармакокинетики, клинической эффективности и переносимости пероральных лекарственных форм a-адреноблокаторов модифицированного высвобождения, применяющихся в лечении симптомов нижних мочевых путей у пациентов с доброкачественной гипертрофией предстательной железы. Рассмотрены следующие лекарственные формы: доксазозин ГИТС, альфузозин замедленного и контролируемого высвобождения, тамсулозин модифицированного и контролируемого высвобождения.
Full Text
References
- Chung M, Vashi V. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol 1999;48:678-87.
- Os I, Stokke HP. for Doxazosin Investigators' Study Group. Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. J Cardiovasc Pharmacol 1999;33(5):791-97.
- Goldsmith DR, Plosker GL. Doxazosin gastrointestinal therapeutic system: a review of its use in benign prostatic hyperplasia. Drugs 2005;65:2037-47.
- Guay DR. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for the symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother 2004;2:14-23. Van Kerrebroeck EV. The efficacy and safety of a new once-a-day formula tion of an а-blocker. Eur Urol 2001; 39(Suppl. 6):19-26.
- Ahtoy P, Chretien P, Dupain T, et al. Alfuzosin an alpha 1 -adrenoreceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. Int J Clin Pharmacol Ther 2002;40:289-94.
- Rauch C, et al. Bioequivalence study of a new once a day controlled release alfuzosin formulation with the 5 mg twice daily formulation. J Urol 2000;164(Suppl. 4):306.
- Michel MC, Grubbel B, Taguchi K, et al. Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned a1-adrenoreceptor subtypes and in human prostate. J Auton Pharmacol 1996; 16:21-28.
- Sato S, Ohtake A, Matsushima H, et al. Pharmacological effect of tamsulosin in relation to dog plasma and tissue concentrations: prostatic and urethral retention possibly contributes to uroselectivity of tamsulosin. J Pharmacol Exp Ther 2001;296:697-703.
- Schulman CC. Tamsulosin modified release and oral controlled absorption system in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Expert Opin Drug Metab Toxicol 2008;4(6):771-82.
- Neill MG, Shahani R, Zlotta AR. Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. Therap Clin Risk Management 2008;4(1):11-18.
- Michel MC, Bressel HU, Mehlburger L, et al. Tamsulosin: real life clinical experience in 19365 patients. Eur Urol 1998; 34(Suppl. 2):37-45.
- Astellas Europe. Summary of product characteristics (SmPc): Tamsulosin modified release (MR) 0,4 mg. Astellas Europe, 2007.
- Lepor H, for the Tamsulosin investigator group. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology 1998;51:892-900.
- Narayan P, Tewari A. A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 1998; 160:1701 -06.
- Michel MC, Korstanje C, Krauwinkel W, et al. The pharmacokinetic profile of tamsulosin oral controlled absorption system (OCAS®). Eur Urol 2005;4(Suppl. 2):15-24.
- Chapple CR, Lorenz J, Mortensen R, et al. Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): efficacy and tolerability in a phase 2b dose-response study. Eur Urol 2005;4(Suppl. 2):25-32.
- Tubaro A, Batista JE, Berges R, et al. Future directions in evaluating nocturia and its impact in patients with LUTS/BPH. Eur Urol 2006;5:19-21.
- Speaman M. Efficacy and safety of tamsulosin OCAS. BJU International 2006; 98(Suppl. 2):13-1 7.
Supplementary files
